Chilblain-Like Lesions during COVID-19 Pandemic: The State of the Art

Bassi, Andrea; Russo, Teresa; Argenziano, Giuseppe; Mazzatenta, Carlo; Venturini, Elisabetta; Neri, Iria; Piccolo, Vincenzo

doi:10.3390/life11010023

Cited by 17 publications

(23 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, a high number of cutaneous manifestations have also been reported. Acral lesions resembling those of chilblains are the most reported signs in young adults with a pauci or asymptomatic viral course, 3 whereas maculo-papular and vesicular rashes are the most common in middle-aged patients. [4][5][6] It is still debated whether the skin manifestations are a direct consequence of COVID-19 pathogenicity or a consequence of thrombogenic and immune deregulatory responses triggered by SARS-CoV-2 infection.…”

Section: Introductionmentioning

confidence: 99%

Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management

Starace

Iorizzo²,

Sechi

et al. 2021

JAAD International

View full text Add to dashboard Cite

Background Cutaneous manifestations of COVID-19 may be useful disease markers and prognostic indicators. Recently, post-infectious telogen effluvium and trichodynia have also been reported. Objective To evaluate the presence of trichodynia and telogen effluvium in patients with COVID-19 and describe their characteristics in relation to other signs and symptoms of the disease. Methods Patients with a history of COVID-19 presenting to the clinics of a group of hair experts because of telogen effluvium and/or scalp symptoms, were questioned with regards about their hair signs and symptoms in relation to the severity of COVID-19 and associated symptoms. Results Data from 128 patients were collected. Telogen effluvium was observed in 66.3% of patients and trichodynia in 58.4%. Trichodynia was associated to telogen effluvium in 42.4% of cases and was associated to anosmia and ageusia in 66.1% and 44.1% of cases, respectively. In the majority of patients (62.5%), hair signs and symptoms started within the first month post-COVID-19 diagnosis and in 47.8% of patients after 12 weeks or more. Limitations Recruitment of patient in specialized hair clinics, lack of a control group, and lack of recording of patient comorbidities. Conclusion The severity of the post-viral telogen effluvium observed in patients with a history of COVID-19 infection is influenced by COVID-19 severity. We identified an early onset (<4 weeks) and a late onset (>12 weeks) telogen effluvium.

show abstract

Section: Introductionmentioning

confidence: 99%

Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management

Starace

Iorizzo²,

Sechi

et al. 2021

JAAD International

View full text Add to dashboard Cite

show abstract

“…CLL are similar in morphology to chilblains, located mostly on the feet, with acrocyanosis and erythematous–oedematous lesions, or in some cases, bullous and necrotic lesions [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Prognosis of rash and chilblain-like lesions among outpatients with COVID-19: a large cohort study

Mascitti

Jourdain

Bleibtreu

et al. 2021

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

In a large regional observational cohort study of adult (≥ 18 years), outpatients with COVID-19, prevalence, characteristics, and outcome of patients with rash and/or chilblain-like lesions (CLL), compared with population without cutaneous features, were studied. In total, 28,957 outpatients were included; the prevalence of rash and CCL were 9.5% and 3.7%, respectively. Presence of rash was significantly associated with presence of asthenia, shivers or myalgia, respiratory and gastro-intestinal symptoms, and anosmia/ageusia. The presence of CCL was associated with chest pain, chest oppression, nausea/vomiting, and anosmia/ageusia. Patients with CCL were significantly less prone to an unfavourable outcome (hospitalization or death).

show abstract

“…After an initial phase of confusion and disagree among researchers, CLL are nowadays considered a highly likely immune-mediated reaction to SARS-CoV-2 usually observed in healthy asymptomatic young people, whose COVID status is often unremarkable. [1][2][3][4][5][6] It has been postulated that this apparent contradiction could be explained as virus-induced interferonopathy associated with a strong activation of innate immune system and fast clearance of antibodies. 7,8 Recently, Davido et al 9 reported a similar case in a 41-yearold woman developing 'blue toes' after BNT162b2 mRNA COVID-19 vaccine.…”

mentioning

confidence: 99%

BNT162b2 mRNA COVID‐19 vaccine‐induced chilblain‐like lesions reinforces the hypothesis of their relationship with SARS‐CoV‐2

Piccolo

Bassi

Argenziano

et al. 2021

Acad Dermatol Venereol

Self Cite

View full text Add to dashboard Cite

Chilblain-Like Lesions during COVID-19 Pandemic: The State of the Art

Cited by 17 publications

References 23 publications

Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management

Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management

Prognosis of rash and chilblain-like lesions among outpatients with COVID-19: a large cohort study

BNT162b2 mRNA COVID‐19 vaccine‐induced chilblain‐like lesions reinforces the hypothesis of their relationship with SARS‐CoV‐2

Contact Info

Product

Resources

About